Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$237.2M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1725.27%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$738.3M
Q3 2024
Cash
Q3 2024
P/E
-9.098
Nov 29, 2024 EST
Free Cash Flow
-$128.9M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $31.07M $29.87M $19.13M $15.24M $8.610M $1.900M $1.080M
YoY Change 4.02% 56.18% 25.51% 77.0% 353.16% 75.93%
% of Gross Profit
Research & Development $141.8M $85.28M $81.76M $64.92M $37.05M $11.88M $3.490M
YoY Change 66.27% 4.31% 25.95% 75.23% 211.84% 240.4%
% of Gross Profit
Depreciation & Amortization $29.00K $43.00K $41.00K $17.00K
YoY Change -32.56% 4.88% 141.18%
% of Gross Profit
Operating Expenses $141.8M $85.28M $81.76M $64.92M $37.05M $13.78M $4.560M
YoY Change 66.27% 4.31% 25.95% 75.23% 168.84% 202.19%
Operating Profit -$172.9M -$115.2M -$100.9M -$80.15M -$45.65M
YoY Change 50.12% 14.14% 25.87% 75.58%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $3.099M $739.0K $109.0K $950.0K $0.00 -$62.15M $0.00
YoY Change 319.35% 577.98% -88.53% -100.0%
% of Operating Profit
Other Income/Expense, Net $3.862M $1.900M -$5.790M $0.00
YoY Change -132.82%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$151.8M -$112.0M -$100.8M -$79.21M -$43.76M -$81.71M -$4.560M
YoY Change 35.46% 11.17% 27.23% 81.01% -46.44% 1691.89%
Income Tax $0.00 $0.00 $0.00 $24.00K
% Of Pretax Income
Net Earnings -$151.8M -$112.0M -$100.8M -$79.21M -$43.76M -$81.71M -$4.560M
YoY Change 35.46% 11.17% 27.23% 81.02% -46.45% 1691.89%
Net Earnings / Revenue
Basic Earnings Per Share -$2.89 -$2.87 -$2.89
Diluted Earnings Per Share -$2.89 -$2.87 -$2.89 -$2.52 -$2.90 -$3.021M -$168.6K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $550.0M $351.4M $188.3M $268.4M $136.4M $76.00M $600.0K
YoY Change 56.5% 86.68% -29.86% 96.77% 79.47% 12566.67%
Cash & Equivalents $234.2M $249.8M $150.5M $187.2M $64.80M $76.00M $600.0K
Short-Term Investments $315.8M $101.7M $37.78M $81.10M $71.60M
Other Short-Term Assets $9.952M $3.724M $5.324M $3.000M $1.600M $1.200M $0.00
YoY Change 167.24% -30.05% 77.47% 87.5% 33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $560.0M $355.2M $193.6M $271.3M $138.0M $77.10M $600.0K
YoY Change 57.66% 83.47% -28.65% 96.59% 78.99% 12750.0%
Property, Plant & Equipment $1.026M $1.289M $1.549M $1.800M
YoY Change -20.4% -16.79% -13.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $19.28M
YoY Change
Other Assets $0.00 $108.0K $417.0K $200.0K $100.0K $0.00 $0.00
YoY Change -100.0% -74.1% 108.5% 100.0%
Total Long-Term Assets $20.31M $1.397M $1.966M $2.000M $100.0K $100.0K $100.0K
YoY Change 1353.76% -28.94% -1.7% 1900.0% 0.0% 0.0%
Total Assets $580.3M $356.6M $195.5M $273.3M $138.1M $77.20M $700.0K
YoY Change
Accounts Payable $7.038M $7.968M $6.706M $3.400M $900.0K $1.400M $100.0K
YoY Change -11.67% 18.82% 97.24% 277.78% -35.71% 1300.0%
Accrued Expenses $12.09M $11.12M $18.42M $9.700M $8.300M $1.000M $200.0K
YoY Change 8.77% -39.66% 89.92% 16.87% 730.0% 400.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.13M $19.08M $25.13M $13.10M $9.400M $2.300M $200.0K
YoY Change 0.24% -24.06% 91.82% 39.36% 308.7% 1050.0%
Long-Term Debt $24.96M $9.541M $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change 161.65%
Other Long-Term Liabilities $873.0K $1.384M $1.311M $1.500M $0.00
YoY Change -36.92% 5.57% -12.6%
Total Long-Term Liabilities $25.84M $10.93M $1.311M $1.500M $0.00 $0.00 $0.00
YoY Change 136.49% 733.33% -12.6%
Total Liabilities $44.97M $30.01M $26.44M $14.60M $9.400M $2.300M $200.0K
YoY Change 49.84% 13.5% 81.09% 55.32% 308.7% 1050.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 52.57M 38.98M 34.83M
Diluted Shares Outstanding 52.57M 38.98M 34.83M 31.46M 15.07M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.1582 Billion

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 60 full-time employees. The company went IPO on 2019-06-20. The firm is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.

Industry: Pharmaceutical Preparations Peers: CHINOOK THERAPEUTICS, INC. Celldex Therapeutics, Inc. VERACYTE, INC. CATALYST PHARMACEUTICALS, INC. Deciphera Pharmaceuticals, Inc. DYNAVAX TECHNOLOGIES CORP Syndax Pharmaceuticals Inc SpringWorks Therapeutics, Inc. Zentalis Pharmaceuticals, Inc.